Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227323 | 0.85 | PTK2 (0.52) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL30099805 | 0.83 | NOTUM (0.48) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2036063 | 0.83 | NOTUM (0.48) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL21695369 | 0.82 | NOTUM (0.50) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2629363 | 0.82 | NOTUM (0.47) | NOTUMRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2216038 | 0.80 | NPC1 (0.59) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2629365 | 0.80 | NOTUM (0.56) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL1723145 | 0.80 | NOTUM (0.56) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL26764538 | 0.80 | NOTUM (0.46) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL1379623 | 0.80 | HCAR3 (0.59) | NOTUMRAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | claimed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2024046512-A2 | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10556889-B1 | Salvinorin derivatives | Blue Sky Pharmaceuticals, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| WO-2010092386-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092387-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010013161-A1 | FLUORINATED HETEROARYLS | PFIZER INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-2121137-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009127949-A1 | 4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008075005-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NOTUM 3016/4885RAB9A 1597/4885MAPT 1600/4885 |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | F12, XDH, REN | NOTUM 3593/4885RAB9A 951/4885MAPT 3277/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | NOTUM 3016/4885RAB9A 1597/4885MAPT 1600/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | NOTUM 1504/4885RAB9A 667/4885MAPT 1432/4885 |
| US-10556889-B1 | Salvinorin derivatives | OPRD1, OPRK1, OPRL1 | NOTUM 4094/4885RAB9A 1009/4885MAPT 4659/4885 |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | NOTUM 3006/4885RAB9A 747/4885MAPT 3226/4885 |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | GCKR, GCK, HK1 | NOTUM 2941/4885RAB9A 3615/4885MAPT 3304/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | NOTUM 1442/4885RAB9A 748/4885MAPT 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.